These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37982440)

  • 1. A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes.
    Zenebe B; Nigussie H; Belay G; Seboka N
    Hematology; 2023 Dec; 28(1):2284038. PubMed ID: 37982440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A; Eskazan AE
    Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unique BCR-ABL1 transcript with the insertion of intronic sequence from BCR and ABL1 genes in a patient with Philadelphia-positive chronic myeloid leukemia: a case study.
    Sadia H; Siddiqui RT; Nasim A
    Cancer Genet Cytogenet; 2010 Aug; 201(1):57-61. PubMed ID: 20633771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
    Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
    Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
    Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
    Hanfstein B; Lauseker M; Hehlmann R; Saussele S; Erben P; Dietz C; Fabarius A; Proetel U; Schnittger S; Haferlach C; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
    Haematologica; 2014 Sep; 99(9):1441-7. PubMed ID: 24837466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of
    Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
    Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G; Hamid M; Jalaeikhoo H
    Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival.
    Romero-Morelos P; González-Yebra AL; Herrerías-García A; Ruíz-Velázquez FA; Bueno-Rosario LJ; González-Yebra B
    Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India.
    Sazawal S; Chhikara S; Singh K; Chaubey R; Mahapatra M; Seth T; Saxena R
    Indian J Pathol Microbiol; 2019; 62(2):256-260. PubMed ID: 30971550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequencies of BCR::ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis.
    Romero-Morelos P; González-Yebra AL; Muñoz-López D; Lara-Lona E; González-Yebra B
    Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
    Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
    Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
    Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
    Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of major
    Genthon A; Nicolini FE; Huguet F; Colin-Gil C; Berger M; Saugues S; Janel A; Hayette S; Cohny-Makhoul P; Cadoux N; Cayuela JM; Campos L; Guyotat D; Flandrin-Gresta P
    Oncotarget; 2020 Jun; 11(26):2560-2570. PubMed ID: 32655840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
    Jain P; Kantarjian H; Patel KP; Gonzalez GN; Luthra R; Kanagal Shamanna R; Sasaki K; Jabbour E; Romo CG; Kadia TM; Pemmaraju N; Daver N; Borthakur G; Estrov Z; Ravandi F; O'Brien S; Cortes J
    Blood; 2016 Mar; 127(10):1269-75. PubMed ID: 26729897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
    Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
    Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.